Biomarkers

Extracellular vesicles in Parkinson’s disease 3:00
Extracellular vesicles in Parkinson’s disease
Tiago Outeiro • 25 Apr 2023
The promise of proteomics in sleep medicine 2:07
The promise of proteomics in sleep medicine
Emmanuel Mignot • 11 May 2023
Latest developments in Parkinson’s disease biomarkers 6:10
Latest developments in Parkinson’s disease biomarkers
Andrea Pilotto • 23 Mar 2023
Key findings from Phase IIa study of PrimeC in ALS patients 3:07
Key findings from Phase IIa study of PrimeC in ALS patients
Shiran Salomon-Zimri • 27 Mar 2023
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial 10:55
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial
Shiran Salomon-Zimri • 27 Mar 2023
Brain imaging signatures to predict conversion risk in iRBD 1:25
Brain imaging signatures to predict conversion risk in iRBD
Shady Rahayel • 16 Apr 2023
Early diagnosis of Parkinson’s disease: biomarkers & provocative tests 3:43
Early diagnosis of Parkinson’s disease: biomarkers & provocative tests
Michael Ugrumov • 30 Mar 2023
Blood-based biomarkers of PD at the prodromal stage 2:47
Blood-based biomarkers of PD at the prodromal stage
Michael Ugrumov • 30 Mar 2023
IL-6 receptor antagonists co-administered with corticosteroids to treat temporal arteritis 5:27
IL-6 receptor antagonists co-administered with corticosteroids to treat temporal arteritis
Bruno Gran • 30 Mar 2023
Temporal arteritis: treatment duration and disease monitoring 2:50
Temporal arteritis: treatment duration and disease monitoring
Bruno Gran • 30 Mar 2023
Machine learning-based prediction of cognitive decline in Parkinson’s disease 2:37
Machine learning-based prediction of cognitive decline in Parkinson’s disease
Joshua Harvey • 9 Mar 2023
Controversies in MS: prodrome, DMTs & biomarkers 1:11
Controversies in MS: prodrome, DMTs & biomarkers
Celia Oreja-Guevara • 24 Mar 2023
GFAP and NfL as biomarkers in NMOSD 3:31
GFAP and NfL as biomarkers in NMOSD
Celia Oreja-Guevara • 24 Mar 2023
GFAP: a potential biomarker for progression in MS 1:31
GFAP: a potential biomarker for progression in MS
Elias Sotirchos • 27 Feb 2023
The development of clinically useful biomarkers in MS 2:59
The development of clinically useful biomarkers in MS
Shane Arsenault • 20 Feb 2023
Molecular mechanisms associated with MS progression, severity and phenotype 7:58
Molecular mechanisms associated with MS progression, severity and phenotype
Peter Kosa • 28 Feb 2023
The content of VJNeurology is intended for healthcare professionals